Mahshid Zamani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mahshid Zamani has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
- Nepton Soltani
Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
1 shared publication
Latest Publications
- Open Access
- 16 April 2025
- Published by MDPI AG in Preprints.org
The Role of Metformin in ECM-Based 3D Cell Culture Models: A Mini-Review on Therapeutic Potentials
Metformin, a cornerstone treatment for type 2 diabetes, has recently emerged as a multifunctional therapeutic agent with applications extending far beyond glycemic control. This mini-review explores its promising roles within extracellular matrix (ECM)-based three-dimensional (3D) cell culture models, which closely mimic the in vivo cellular microenvironment. Through modulation of key pathways—including AMPK activation, inhibition of TGF-β signaling, suppression of aerobic glycolysis, and regulation of microRNAs—metformin exerts profound effects on ECM remodeling, fibrosis attenuation, and tumor progression. Furthermore, its integration into ECM-inspired drug delivery systems and regenerative scaffolds has shown great potential in applications such as diabetic wound healing, bone repair, and implant integration. Collectively, current findings highlight metformin as a versatile agent capable of modulating ECM biology in disease-specific 3D systems, paving the way for innovative therapeutic strategies in oncology, metabolic disorders, and tissue engineering.
- 16 April 2025
- Published by MDPI AG in Preprints.org
Open AccessThe Role of Metformin in ECM-Based 3D Cell Culture Models: A Mini-Review on Therapeutic Potentials
Metformin, a cornerstone treatment for type 2 diabetes, has recently emerged as a multifunctional therapeutic agent with applications extending far beyond glycemic control. This mini-review explores its promising roles within extracellular matrix (ECM)-based three-dimensional (3D) cell culture models, which closely mimic the in vivo cellular microenvironment. Through modulation of key pathways—including AMPK activation, inhibition of TGF-β signaling, suppression of aerobic glycolysis, and regulation of microRNAs—metformin exerts profound effects on ECM remodeling, fibrosis attenuation, and tumor progression. Furthermore, its integration into ECM-inspired drug delivery systems and regenerative scaffolds has shown great potential in applications such as diabetic wound healing, bone repair, and implant integration. Collectively, current findings highlight metformin as a versatile agent capable of modulating ECM biology in disease-specific 3D systems, paving the way for innovative therapeutic strategies in oncology, metabolic disorders, and tissue engineering.